Illumina is improving human health by unlocking the power of the genome. The company provides sequencing and array technologies that fuel genomic discoveries, enabling life-changing breakthroughs in cancer research, reproductive health, genetic disease understanding, and translational and consumer genomics. As a global genomics leader, Illumina innovates to make genomics more accessible to researchers, clinicians, and patients worldwide.
Founded in 1998 and headquartered in San Diego, California, Illumina develops integrated systems for the analysis of genetic variation and function. The company's comprehensive portfolio spans high-throughput sequencing platforms like NovaSeq X and NextSeq systems, microarray scanners, library preparation kits, and informatics solutions including BaseSpace Sequence Hub and DRAGEN. By empowering researchers and clinicians with tools that improve cancer treatments, change disease trajectories, and protect future generations, Illumina is transforming the future of precision health and making genomics useful for all.
